首页 工具
登录
购物车

搜索结果

Search Results for " c myc peptide trifluoroacetate "
Targets Recommended: Others

1

抑制剂 & 化合物

9

重组蛋白

如果没找到您满意的产品或者您对产品有其他要求,可以联系我们专业顾问为您提供针对性的合理建议。     QQ咨询       网站留言咨询

提交您的定制咨询

点击图片重新获取验证码
Cat. No. Product Name Target Signaling Pathways
TP1315 c-Myc Peptide Trifluoroacetate

Others Others
c-Myc Peptide Trifluoroacetate (145646-22-6 free base) 是一种合成肽,对应于人类 c-myc 蛋白的 C 末端氨基酸 (410-419),参与调控生长相关基因的转录。

化合物

c-Myc Peptide Trifluoroacetate
Cat.No: TP1315
Synonym:
Target: Others
Cat. No. Product Name Species Expression System
TMPK-01450 HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated

KRAS1,MHC,K-RAS4B,KRAS,CFC2,K-RAS...

Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01456 HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)

KRAS2,NS,MHC,C-K-RAS,KRAS1,K-RAS2A,K-RAS2B...

Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01451 HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)

NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK2,MHC,KI-RAS,KRAS,...

Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01491 HLA-A*02:01&B2M&HBV (FLLTRILTI) Monomer Protein, Human, MHC (His & Avi), Biotinylated

MHC,HBV,Hepatitis B virus

Human HEK293 Cells
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7).
TMPK-01501 HLA-A*02:01&B2M&HBV (FLLTRILTI) Tetramer Protein, Human, MHC (His & Avi)

MHC,Hepatitis B virus,HBV

Human HEK293 Cells
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7).
TMPK-01505 HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer Protein, Human, MHC (His & Avi), Biotinylated

E7,MHC,HPV16

Human HEK293 Cells
HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody.
TMPK-01492 HLA-A*02:01&B2M&HBV (FLLTRILTI) Monomer Protein, Human, MHC (His & Avi)

Hepatitis B virus,HBV,MHC

Human HEK293 Cells
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7).
TMPK-01504 HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Tetramer Protein, Human, MHC (His & Avi)

MHC,HPV16,E7

Human HEK293 Cells
HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody.
TMPK-01506 HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer Protein, Human, MHC (His & Avi)

HPV16,E7,MHC

Human HEK293 Cells
HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody.

重组蛋白

HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01450
Species: Human
Expression System: HEK293 Cells
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01456
Species: Human
Expression System: HEK293 Cells
HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01451
Species: Human
Expression System: HEK293 Cells
HLA-A*02:01&B2M&HBV (FLLTRILTI) Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01491
Species: Human
Expression System: HEK293 Cells
HLA-A*02:01&B2M&HBV (FLLTRILTI) Tetramer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01501
Species: Human
Expression System: HEK293 Cells
HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01505
Species: Human
Expression System: HEK293 Cells
HLA-A*02:01&B2M&HBV (FLLTRILTI) Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01492
Species: Human
Expression System: HEK293 Cells
HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Tetramer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01504
Species: Human
Expression System: HEK293 Cells
HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01506
Species: Human
Expression System: HEK293 Cells
TargetMol Loading
联系我们
400-820-0310

上海市静安区江场三路238号8楼